AEGiS-10CROI: Impact on Fat Loss of ZDV + 3TC Backbone: Abdominal CT-scan Sub-study of Study DMP 266-006.

10th Conference on Retroviruses and Opportunistic Infections


Boston, MA USA - February 10 -14, 2003

Print this Article


Impact on Fat Loss of ZDV + 3TC Backbone: Abdominal CT-scan Sub-study of Study DMP 266-006.

Conf Retroviruses Opportunistic Infect 2003 Feb 10-14;10th: abstract no. 737
Tashima K, Morales-Ramirez J, Butcher D, Barros C, Maa J, Bessen L, Aznar E; Miriam Hosp,Providence RI

BACKGROUND: Lipodystrophy, or more specifically, fat redistribution (subcutaneous fat loss and/or visceral fat accumulation) is thought to be a complication of the severity and duration of HIV infection and HAART, associated with both nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors. In a previous analysis of this sub-study, the results reflected loss of subcutaneous fat in all 3 regimens. This analysis assessed the relative NRTI contribution on fat loss over a 2-3 yr period.

METHODS: Non-randomized, cross-sectional, post-hoc sub-study of DMP 266-006 comparing 3 different regimens in therapy-naïve subjects: efavirenz (EFV) + zidovudine (ZDV) + lamivudine (3TC), indinavir (IDV) + ZDV + 3TC, and EFV + IDV. Consenting subjects underwent abdominal CT scans including a section at the level of the umbilicus or fourth lumbar vertebra. CT scans were performed locally at the next scheduled study visit with a follow-up scan 1 yr later. An independent, central reader read all scans in a blinded fashion. We compared changes in fat redistribution of patients receiving NRTIs versus an NRTI-sparing regimen. Comparisons were made using the Wilcoxon test.

RESULTS: A total 373 subjects enrolled in this sub-study. Demographic and baseline characteristics of the 2 groups were comparable. The median time across groups from study start to first scan was 738 days and to the follow-up scan, 1,106 days; 277 subjects had both first and second scans. The median changes in subcutaneous fat between the first and second scans can be found in the chart below: [table: see text]

CONCLUSIONS: These data show that subcutaneous fat loss in patients receiving NRTIs was not significantly different than those observed in the NRTI-sparing arm, suggesting that NRTIs were not exclusively associated with fat loss in this study.

Keywords: AEGIS, Lamivudine, Zidovudine, Oxazines, Reverse Transcriptase Inhibitors, efavirenz, Anti-HIV Agents, HIV Infections, Indinavir, Antiretroviral Therapy, Highly Active, Fats, HIV Protease Inhibitors, Tomography, X-Ray Computed, Lipodystrophy, Cross-Sectional Studies, Human, radiography

030210
737

Copyright © 2003 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.